

### ISSUE @ A GLANCE


**Heart failure and its causes: high blood pressure, atrial fibrillation, radiotherapy, and chemotherapy**
*T.F. Lüscher*
**3827**

### CardioPulse

**EHJ 2018 Editorial Board Meeting**
**3832**
**This is YOUR ESC**
*S. Squarta and F. Pinto*
**3835**
**ESH Annual Meeting 2018**
*K. Tsoufis and R. Kreutz*
**3836**
**EuroPrevent 2018**
*J.-P. Schmid*
**3840**
**What is the role of gene testing in athletes with T wave inversion?**
*N. Sahdev, N. Sheikh, and S. Sharma*
**3841**

### EDITOR'S PAGE

**The Impact Factor: sparkling or still?**
*T.F. Lüscher and A.F. Kavaney*
**3844**

### CLINICAL REVIEW

#### Translational medicine

**Pulsatile arterial haemodynamics in heart failure**
*T. Weber and J.A. Chirinos*
**3847**

### FAST TRACK CLINICAL RESEARCH

#### Hypertension



	Crude rate, % (95% CI)	Unadjusted HR (95% CI)	Adjusted HR (95% CI)	Adjusted p-value
SBP <120 mmHg	2.4 (1.8–3.3)	0.95 (0.83–1.41)	1.16 (0.85–2.05)	
SBP 120–129 mmHg	2.6 (2.0–3.4)	1.00 (ref)	1.00 (ref)	0.8888
SBP 130–139 mmHg	3.1 (2.3–4.1)	1.16 (0.79–1.70)	1.12 (0.84–1.97)	
DBP <70 mmHg	3.3 (2.4–4.6)	1.58 (1.06–2.36)	0.93 (0.51–1.70)	
DBP 70–79 mmHg	2.2 (1.7–2.7)	1.00 (ref)	1.00 (ref)	0.0182
DBP 80–89 mmHg	3.6 (2.6–4.9)	1.63 (1.10–2.42)	2.15 (1.22–3.81)	

**Potential impact of the 2017 ACC/AHA Guideline on high blood pressure in normotensive patients with stable coronary artery disease: insights from the CLARIFY registry**

*E. Vidal-Petiot, E. Sorbets, D.L. Bhatt, G. Ducrocq, Y. Elbez, R. Ferrari, I. Ford, J.-C. Tardif, M. Tendera, K.M. Fox, and P.G. Steg, on behalf of the CLARIFY investigators*


**3855**

#### Editorial

**High blood pressure in coronary artery disease: when to start treating and what to target?**
*M. Böhm and F. Mahfoud*
**3864**

### CLINICAL RESEARCH

#### Heart failure/cardiomyopathy



**Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction**

*B.T. Santema, M. Kloosterman, I.C. Van Gelder, I. Mordi, C.C. Lang, C.S.P. Lam, S.D. Anker, J.G. Cleland, K. Dickstein, G. Filippatos, P. Van der Harst, H.L. Hillege, J.M. Ter Maaten, M. Metra, L.L. Ng, P. Ponikowski, N.J. Samani, D.J. Van Veldhuisen, A.H. Zwinderman, F. Zannad, K. Damman, P. Van der Meer, M. Rienstra, and A.A. Voors*

**3867**

**Editorial**

Biomarkers: a window into the pathophysiology of atrial fibrillation in heart failure with reduced vs. preserved ejection fraction  
*M. Nishimura and A.S. Maisel*

3876

**BASIC SCIENCE****Heart failure/cardiomyopathy**

CRISPR/Cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathy  
*D. Mosqueira, I. Mannhardt, J.R. Bhagwan, K. Lis-Slimak, P. Katili, E. Scott, M. Hassan, M. Prondzynski, S.C. Harmer, A. Tinker, J.G.W. Smith, L. Carrier, P.M. Williams, D. Gaffney, T. Eschenhagen, A. Hansen, and C. Denning*

3879

**Editorial**

Disease modelling and drug discovery for hypertrophic cardiomyopathy using pluripotent stem cells: how far have we come?  
*C.K. Lam and J.C. Wu*

3893

**CLINICAL RESEARCH****Prevention and epidemiology**

Long-term heart-specific mortality among 347 476 breast cancer patients treated with radiotherapy or chemotherapy: a registry-based cohort study  
*J. Weverpals, L. Jansen, O.J. Müller, and H. Brenner*

3896

**DISCUSSION FORUM**

More study still needed on the use of bromocriptine in the treatment of peripartum cardiomyopathy  
*J.D. Fett*

3904

Reply to 'More study still needed on the use of bromocriptine in the treatment of peripartum cardiomyopathy'  
*D. Hilfiker-Kleiner, K. Sliwa, and J. Bauersachs*

3905

**CARDIOVASCULAR FLASHLIGHTS**

Intracardiac leiomyomatosis: a rare cause of syncope  
*A.B. Freitas-Ferraz and M.-H. LeBlanc*

3906

Unusual rapid progression of non-bacterial thrombotic endocarditis in a patient with bladder cancer despite undergoing intensification treatment with rivaroxaban for acute venous thromboembolism  
*D. Fujimoto, Y. Mochizuki, K. Nakagiri, and J. Shite*

3907



Open Access Paper



For the podcast associated with this article, please visit <https://academic.oup.com/eurheartj/pages/Podcasts>



Visit EHJ's mobile site  
<https://academic.oup.com/eurheartj>



[www.eurheartj.org](http://www.eurheartj.org)